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OBJECTIVE — To determine whether regular aspirin use (75 mg/day) is independently
associated with cardiovascular disease (CVD) and all-cause mortality in community-based pa-
tients with type 2 diabetes and no history of CVD.
RESEARCH DESIGN AND METHODS — Of the type 2 diabetic patients recruited to
the longitudinal observational Fremantle Diabetes Study, 651 (50.3%) with no prior CVD
history at entry between 1993 and 1996 were followed until death or the end of June 2007,
representing a total of 7,537 patient-years (mean  SD 11.6  2.9 years). Cox proportional
hazards modeling was used to determine independent baseline predictors of CVD and all-cause
mortality including regular aspirin use.
RESULTS — Therewere160deaths(24.6%)duringfollow-up,with70(43.8%)duetoCVD.
InKaplan-Meiersurvivalanalysis,therewasnodifferenceineitherCVDorall-causemortalityin
aspirin users versus nonusers (P  0.52 and 0.94, respectively, by log-rank test). After adjust-
ment for signiﬁcant variables in the most parsimonious Cox models, regular aspirin use at
baseline independently predicted reduced CVD and all-cause mortality (hazard ratio [HR] 0.30
[95% CI 0.09–0.95] and 0.53 [0.28–0.98[, respectively; P  0.044). In subgroup analyses,
aspirin use was independently associated with reduced all-cause mortality in those aged 65
years and men.
CONCLUSIONS — Regular low-dose aspirin may reduce all-cause and CVD mortality in a
primary prevention setting in type 2 diabetes. All-cause mortality reductions are greatest in men
and in those aged 65 years. The present observational data support recommendations that
aspirin should be used in primary CVD prevention in all but the lowest risk patients.
Diabetes Care 33:317–321, 2010
T
he value of low-dose aspirin as pri-
mary prevention for cardiovascular
disease (CVD) in patients with type 2
diabetes remains to be established. The
American Diabetes Association (ADA) (1)
and the European Society of Cardiology
(ESC) and European Society for the Study
of Diabetes (EASD) (2) recommend the use
of aspirin in this situation, but there is no
consistent supportive evidence of reduc-
tions in CVD events or mortality (3–6). In
population-based primary prevention trials
reported to date, only 4% of patients had
type 2 diabetes (7). This low percentage
raises the question of whether the diabetic
subjects were representative. There have
been few such studies in diabetic subjects
speciﬁcally (4,5).
There is a clear need for more data on
the beneﬁts and risks of aspirin for pri-
mary prevention in diabetes. We have,
therefore, examined the relationship be-
tween CVD death and all-cause mortality
in a large, well characterized Australian
community-based cohort of type 2 pa-
tients with no history of CVD.
RESEARCH DESIGN AND
METHODS— The Fremantle Diabe-
tes Study (FDS) was a longitudinal obser-
vational cohort study of patients from a
postalcode–deﬁnedurbancommunityof
120,097 people. Descriptions of recruit-
ment, sample characteristics including
classiﬁcation of diabetes type, and details
of nonrecruited patients have been pub-
lished elsewhere (8). Of 2,258 diabetic
patients identiﬁed between 1993 and
1996, 1,426 (63%) were recruited to the
FDS and 1,294 had type 2 diabetes. Eligi-
ble patients who declined participation
were a mean of 1.4 years older than partic-
ipants, but their sex distribution, the pro-
portion with type 2 diabetes, and their use
of blood glucose–lowering therapies were
similar(8).TheFDSprotocolwasapproved
by the Human Rights Committee at
Fremantle Hospital, and all subjects gave
informed consent before participation.
Baseline and annual assessments
The assessment of each patient at study
entry and at each annual review included
acomprehensivequestionnaireandphys-
icalexamination(8).Inadditiontodetails
of all medical conditions and their man-
agement, demographic, socioeconomic,
and lifestyle data were recorded. Patients
wererequestedtobringallmedicationsto
each visit and details, including doses,
were recorded. Regular aspirin use was
deﬁned as a minimum of 75 mg/day or
300 mg every 2nd day (9). Biochemical
testswereperformedonfastingbloodand
urine samples using standard automated
methods in a single laboratory (8).
Baseline complications were identi-
ﬁed using standard deﬁnitions (10). In
brief, microalbuminuria was deﬁned as a
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of3.0mg/mmol.Theestimatedglomer-
ularﬁltrationratewascalculatedfromthe
serum creatinine (11). Neuropathy was
deﬁned using the clinical portion of the
Michigan Neuropathy Screening Instru-
ment.Retinopathywasdeﬁnedasonemi-
croaneurysmineithereyeorworseand/or
evidence of previous laser treatment on
direct and/or indirect ophthalmoscopy
through dilated pupils and/or more de-
tailed ophthalmological data in patients
assessed for photocoagulation. Patients
were classiﬁed as having coronary heart
disease if there was a history of myocar-
dial infarction, angina, coronary artery
bypass grafting, or angioplasty and as
having cerebrovascular disease if there
was a history of stroke and/or transient
ischemic attack. Peripheral arterial dis-
ease was deﬁned as an ankle brachial in-
dex 0.90 or the presence of a diabetes-
related lower-extremity amputation.
Mortality ascertainment
All deaths and hospital admissions in the
state of Western Australia are recorded in
the Western Australian Data Linkage Sys-
tem (12), which was used to provide FDS
patient outcomes from the beginning of
the study until the end of June 2007.
Causesofdeathwerereviewedindepen-
dently by two physicians and classiﬁed
under the system used in the UK Pro-
spectiveDiabetesStudy(13).Incasesof
discrepant coding, case notes were con-
sulted and a consensus was obtained.
Death from CVD was deﬁned as death
from cardiac or cerebrovascular causes




(version 15.0) was used for statistical
analysis. Data are presented as propor-
tions, mean  SD, geometric mean (SD
range), or, in the case of variables that did
not conform to a normal or log-normal
distribution, median (interquartile
range). For independent samples, two-
way comparisons for proportions were
performed by Fisher exact test, for nor-
mally distributed variables by Student t
test, and for nonnormally distributed
variables by Mann-Whitney U test. Mul-
tiple comparisons for proportions were
performed by Fisher exact test or 
2 test,
for normally distributed variables by one-
way ANOVA, and for nonnormally dis-
tributed variables by Kruskal-Wallis
H-test. A two-tailed signiﬁcance level of
P  0.05 was used throughout.
Kaplan-Meieranalysiswasusedtoas-
sess all-cause mortality and CVD death
with respect to aspirin use. Cox propor-
tional hazards modeling (forward condi-
tional variable entry and removal with
P0.05andP0.10,respectively)was
usedtodetermineindependentbaseline
predictors of all-cause and CVD mortal-
ity. All clinically plausible variables
were considered for entry into the mod-
els, including demographic and diabe-
tes-relatedfactors,thepresenceofother
diabetes complications, and cardiovas-
cular risk factors. The validity of the
proportional hazards assumption was
assessed from log (log[survival]) curves
and examination of time-dependent
covariates.
Table 1—Baseline characteristics of 1,294 FDS participants with type 2 diabetes classiﬁed by






Age (years) 60.7  11.2 67.6  10.1 0.001
Male sex (%) 45.3 52.8 0.008
Ethnic background (%)
Anglo-Celt 62.1 65.0
Southern European 20.0 16.5




Education beyond primary level (%) 73.8 74.6 0.75
Not ﬂuent in English (%) 16.7 13.6 0.14
Currently married/de facto relationship (%) 67.2 64.7 0.38
Smoking status (%) 52.4 36.7
Never
Former 34.4 46.8 0.001
Current 13.3 16.6
Any exercise in past 2 weeks (%) 75.2 69.0 0.014
Alcohol consumption (standard drinks/day) 0 0–0.8 0 0–0.3 0.020
Diabetes duration (years) 3.0 0.8–7.0 5.0 1.4–11.0 0.001
Fasting serum glucose (mmol/l) 8.4 6.8–10.9 8.5 6.9–10.7 0.69
A1C (%) 7.4 6.3–8.7 7.5 6.5–8.9 0.054
Diabetes treatment (% diet/oral agents/insulin 
oral agents) 35.9/55.3/8.8 27.7/57.2/15.1 0.001
BMI (kg/m
2) 29.9  5.4 29.1  5.3 0.007
Abdominal obesity (%; by waist circumference*) 66.2 62.4 0.18
Systolic blood pressure (mmHg) 146  22 156  24 0.001
Diastolic blood pressure (mmHg) 80  11 81  11 0.08
Taking antihypertensive medication (%) 37.5 65.1 0.001
Total serum cholesterol (mmol/l) 5.4  1.1 5.5  1.2 0.45
Serum HDL cholesterol (mmol/l) 1.08  0.33 1.04  0.32 0.015
Serum triglycerides (mmol/l) 1.8 (1.1–3.2) 2.0 (1.1–3.4) 0.039
Lipid-lowering therapy (%) 7.2 14.0 0.001
Regular aspirin use (75 mg/day) 7.7 36.6 0.001
Urinary ACR (mg/mmol) 2.4 (0.6–9.7) 4.0 (0.9–18.0) 0.001
Estimated glomerular ﬁltration rate 60 ml/min
per 1.73 m
2 (%) 13.0 29.2 0.001
Peripheral neuropathy (%) 25.0 37.1 0.001
Any retinopathy (%) 12.7 20.3 0.001
Coronary heart disease (%) 0 57.1 0.001
Cerebrovascular disease (%) 0 21.0 0.001
Peripheral arterial disease (%) 0 60.5 0.001
Data are means  SD, %, median interquartile range, or geometric mean (SD range). *Men 94 cm;
women 80 cm.
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Baseline patient characteristics
Of the 1,294 type 2 patients recruited to
the FDS, 1,276 (98.6%) had complete de-
tails of baseline aspirin use and CVD status
as well as outcomes of interest during fol-
low-up. Of these 651 (51.0%) had no prior
history of coronary heart disease, cerebro-
vascular disease, or peripheral arterial dis-
ease. Compared with the remaining 625
participantswithprevalentCVDatbaseline,
they were signiﬁcantly younger, were less
likely to be male, had shorter diabetes du-
ration, and were less likely to be taking as-
pirin regularly (7.7 vs. 36.6%; P  0.001)
(Table 1). Of the primary prevention sub-
group, 50 (7.7%) were taking aspirin regu-
larly, and all of these patients were taking a
daily dose of 75 mg/day.
Cardiovascular and all-cause
mortality
Between study entry and the end of June
2007, there were 160 deaths (24.6%) in
the primary prevention group during a
total of 7,537 patient-years (11.6  2.9
years) of follow-up, of which 70 (43.8%)
were attributed to CVD. In Kaplan-Meier
survivalanalysis,therewerenosigniﬁcant
differences between aspirin users and
nonusers in terms of CVD or all-cause
mortality(P0.52andP0.94,respec-
tively, by log-rank test). After adjustment
for other signiﬁcant variables, regular as-
pirin use was independently associated
withreducedall-causeandCVDmortality
(Table 2).
In patients aged at least 65 years, as-
pirin use was not signiﬁcantly associated
with CVD or all-cause mortality in unad-
justed Kaplan-Meier analyses (P  0.09
bylog-ranktest),but,afteradjustmentfor
themostparsimoniousCoxmodeloftime
to death, it was a signiﬁcant, independent
predictor of reduced all-cause mortality
(Table 3). In Cox proportional hazards
models, there were no independent asso-
ciations between aspirin use and either
CVD or all-cause mortality in patients
aged 65 years (P  0.56).
The regular use of aspirin had differ-
ent effects by sex. In both men and
women, aspirin use was not signiﬁcantly
associated with CVD or all-cause mortal-
ity in unadjusted Kaplan-Meier analyses
(P  0.09 by log-rank test). In Cox mod-
els, aspirin use was independently associ-
ated with reduced all-cause mortality in
menbutnotinwomen(Table4).Nosuch
reduction was seen for CVD mortality in
men or women (P  0.12).
CONCLUSIONS— We found that
regular use of aspirin by community-
basedpatientswithtype2diabetesandno
prior history of CVD was independently
associatedwithareductioninsubsequent
CVD and all-cause mortality of at least
50%. The effect was most pronounced in
subgroups comprising males and those
patients aged 65 years. Although the
present data are observational, they add
weight to recommendations from bodies
such as ESC, EASD, and ADA (1,2) that
aspirin should be used in a primary pre-
vention setting to reduce the potentially
devastating effects of CVD complicating
type 2 diabetes in all but the lowest risk
patients (those who are young and with-
out recognized vascular risk factors).
IntherecentAntithromboticTrialists’
(ATT) Collaboration meta-analysis of pri-
mary prevention studies of samples
drawn from the general population (6),
“serious vascular events” (primarily non-
fatal myocardial infarction) were reduced
Table 2—Independent determinants of time to CVD and all-cause mortality in FDS primary
prevention subjects
HR (95% CI) P value
Cardiovascular mortality
Age (increase of 10 years) 3.09 (2.27–4.21) 0.001
Diabetes duration (increase of 5 years) 1.27 (1.09–1.49) 0.003
Not ﬂuent in English 0.17 (0.07–0.47) 0.001
BMI (increase of 1 kg/m
2) 0.92 (0.87–0.97) 0.002
ln(urine ACR)* 1.21 (1.02–1.44) 0.034
Regular aspirin use 0.30 (0.09–0.95) 0.041
All-cause mortality
Age (increase of 10 years) 2.15 (1.76–2.62) 0.001
Male sex 1.47 (1.06–2.03) 0.022
Southern European ethnicity 0.63 (0.40–0.98) 0.041
BMI (increase of 1 kg/m
2) 0.93 (0.90–0.97) 0.001
Lipid-modifying therapy 0.30 (0.11–0.82) 0.018
ln(urinary ACR)* 1.36 (1.21–1.52) 0.001
Peripheral neuropathy 1.79 (1.27–2.53) 0.001
Regular aspirin use 0.53 (0.28–0.98) 0.044
ThemostparsimoniousmodelsareshownwithHRs(95%CI).TheHRsforregularaspirinusearethoseafter
adjustment for the signiﬁcant variables in the models. *A 2.72-fold increase in ACR or triglycerides corre-
sponds to an increase of 1 in ln(ACR) or ln(triglycerides), respectively.
Table 3—Independent determinants of time to CVD and all-cause mortality in FDS primary
prevention subjects aged >65 years
HR (95% CI) P value
Cardiovascular mortality
Age (increase of 10 years) 2.98 (1.76–5.04) 0.001
Alcohol consumption 1.09 (1.01–1.17) 0.024
BMI (increase of 1 kg/m
2) 0.91 (0.85–0.97) 0.004
Diabetes duration (increase of 5 years) 1.28 (1.09–1.50) 0.002
Regular aspirin use 0.35 (0.11–1.13) 0.079
All-cause mortality
Age (increase of 10 years) 2.69 (1.83–3.95) 0.001
BMI (increase of 1 kg/m
2) 0.93 (0.89–0.97) 0.002
Diastolic blood pressure (increase of 1 mmHg) 0.98 (0.97–1.00) 0.050
Any exercise 0.59 (0.39–0.91) 0.016
Insulin therapy 1.87 (1.05–3.32) 0.033
ln(urinary ACR)* 1.26 (1.10–1.45) 0.001
Male sex 1.84 (1.22–2.78) 0.004
Southern European ethnicity 0.37 (0.20–0.68) 0.001
Regular aspirin use 0.40 (0.19–0.84) 0.015
ThemostparsimoniousmodelsareshownwithHRs(95%CI).TheHRsforregularaspirinusearethoseafter
adjustment for the signiﬁcant variables in the models. *A 2.72-fold increase in ACR or triglycerides corre-
sponds to an increase of 1 in ln(ACR).
Ong, Davis, and Davis
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010 319by the use of low-dose aspirin, but there
was no effect on vascular mortality. In
376 diabetic patients allocated either as-
pirin or placebo, there was a nonsigniﬁ-
cant trend toward beneﬁt for serious
vascular events with a rate ratio of 0.88
(95% CI 0.67–1.15) favoring aspirin, but
mortality data were not reported for this
small subgroup (6). In a randomized trial
of aspirin in 3,711 patients with type 1 or
type 2 diabetes and retinopathy with or
without CVD recruited in the early 1980s
and followed for 5 years (14), there were
nonsigniﬁcant reductions of 13 and 9%,
respectively, for CVD and all-cause mor-
tality in aspirin-treated subjects.
Two more recent intervention trials
have examined the role of aspirin as pri-
mary prevention for patients with diabe-
tes. The Prevention of Progression of
Arterial Disease and Diabetes (PO-
PADAD) trial in 1,276 Scottish patients
with type 1 or 2 diabetes and asymptom-
atic peripheral vascular disease followed
for a median of 6.7 years (4) and the Jap-
anese Primary Prevention of Atheroscle-
rosis with Aspirin for Diabetes (JPAD)
trial in 2,539 Japanese with type 2 diabe-
tes followed for a median of 4.4 years (5)
did not show that aspirin therapy pre-
vented a composite vascular end point.
The JPAD trial provided some evidence
that aspirin-treated patients had lower
coronary and cerebrovascular mortality,
but there was only one death from coro-
nary or cerebrovascular causes in the as-
pirin group and 10 in the control group.
Indeed, the low event rates in these trials
and their consequently limited statistical
power have been highlighted (15). In the
present study, the numbers of total and
CVD deaths were much greater, due
mainly to the longer follow-up period.
Older individuals and men are at in-
creased risk of vascular events (6), and
our ﬁndings suggest that aspirin therapy
is particularly beneﬁcial in these sub-
groups in type 2 diabetes. In the general
population trials included in the recent
ATT meta-analysis of data from 95,000
subjects, there was no convincing evi-
denceofaninteractionbetweenageorsex
and aspirin effects on CVD or all-cause
mortality (6,16). However, these analyses
included a majority of women with al-
most 40,000 low CVD–risk subjects from
the Women’s Health Initiative (WHI)
study (17,18). Consistent with our data,
the JPAD study found that the reduction
inincidenceofatheroscleroticeventswith
aspirin was seen mainly in patients with
type 2 diabetes who were at least 65 years
of age (5). However, neither the PO-
PADAD (4) nor JPAD (5) study was able
to identify any sex-speciﬁc differences.
The risk of aspirin-associated hemor-
rhage needs to be balanced against CVD
and mortality beneﬁts. In the present
study, aspirin use was not associated with
increased all-cause mortality. In addition,
aspirin was not independently associated
with hospitalization for complicated pep-
tic ulcer disease in the FDS cohort as a
whole(19).Althoughextracranialhemor-
rhage rates were increased in both the
ATT meta-analysis (6) and the JPAD trial
(5), these were mainly nonfatal episodes.
Stroke-related mortality in the ATT meta-
analysis (6), due mainly to hemorrhagic
events, was only statistically signiﬁcant if
datafromprimaryandsecondarypreven-
tionstudieswerepooled.IntheJPADtrial
no signiﬁcant increase in hemorrhagic
stroke was identiﬁed (5). A recent Swed-
ish record linkage study (20) showed an
increase in all-cause mortality in aspirin-
treated type 2 diabetic patients, especially
in elderly patients, but the range of vari-
able was not as extensive as in the present
study.
Our study had limitations. The FDS
data were observational, but there is little
evidencethatestimatesofinterventionef-
fects in well conducted observational
studies are consistently larger than or
qualitatively different from those ob-
tained in randomized controlled trials
(21). We were unable to address the in-
ﬂuence of changes in therapies, including
aspirin,duringfollow-up.Nevertheless,if
patients not taking aspirin at baseline
started this therapy subsequently, this
would have attenuated the protective ef-
fect of aspirin we identiﬁed. Our sample
size was greater than that in some pub-
lishedanalyses(6)butsmallerthanthatin
several intervention trials (4,5,14). How-
ever, the strengths of our study include
the representative nature of the study
sample and a relatively long duration of
follow-up with a consequently high event
rate. In addition, the Western Australian
DataLinkageSystemcapturesbothpublic
and private hospital admissions in West-
ernAustralia(11)withlowratesofcoding
errors (22) and migration out of the state
of Western Australia (23).
In the absence of valid data from in-
tervention trials conducted speciﬁcally in
diabetic patients or in general population
samples with an identiﬁed subgroup with
diabetes (4–6), the marked protection
against mortality seen in aspirin-treated
patients in the present study supports use
of the drug in patients with type 2 diabe-
tes and no prior CVD history. Conﬁrma-
tory data may come from large scale
intervention trials currently in progress
(24,25).
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Table 4—Independent determinants of time to CVD and all-cause mortality in FDS primary
prevention male subjects
HR (95% CI) P value
Cardiovascular mortality
Age (increase of 10 years) 2.58 (1.61–4.15) 0.001
BMI (increase of 1 kg/m
2) 0.87 (0.80–0.95) 0.003
ln(urinary ACR)* 1.44 (1.14–1.81) 0.002
Aboriginal background 30.49 (2.72–341.82) 0.006
Not ﬂuent in English 0.14 (0.02–1.04) 0.054
Regular aspirin use 0.20 (0.03–1.51) 0.12
All-cause mortality
Age (increase of 10 years) 2.43 (1.82–3.24) 0.001
BMI (increase of 1 kg/m
2) 0.94 (0.89–0.99) 0.019
ln(urinary ACR)* 1.34 (1.16–1.55) 0.001
Aboriginal background 13.03 (1.52–111.54) 0.019
Southern European ethnicity 0.43 (0.22–0.83) 0.013
Regular aspirin use 0.34 (0.12–0.93) 0.035
ThemostparsimoniousmodelsareshownwithHRs(95%CI).TheHRsforregularaspirinusearethoseafter
adjustment for the signiﬁcant variables in the models. *A 2.72-fold increase in ACR or triglycerides corre-
sponds to an increase of 1 in ln(ACR).
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